David Reardon, MD | Authors

July 24, 2020

David Reardon, MD, discusses the interim results and toxicity with INO-5401 and INO-9012 delivered intramuscularly with electroporation in combination with cemiplimab in patients with newly diagnosed glioblastoma.

February 10, 2016

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the future of immunotherapy in glioblastoma and how rindopepimut fits into that paradigm.

January 29, 2016

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses identifying certain characteristics in a patient's brain tumor in order to administer better treatment.

November 20, 2015

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, on the need to identify glioblastoma (GBM) patients with the EGFRvIII mutation in their tumor.